Tianjin Lisheng Pharmaceutical's (SHE:002393) attributable profit rose to 342.9 million yuan in the first half of 2025 from 102.4 million yuan a year prior, a Friday Hong Kong bourse filing by parent Tianjin Development (HKG:0882) said.
Earnings per share came in at 1.33 yuan, up from 0.40 yuan in the year-ago period.
Total operating income rose to 731.5 million yuan in the six months from 744.6 million yuan in the first half of 2024.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.